ENOV · CIK 0001420800
What Enovis Corporation told the SEC could break it.
2 self-disclosed vulnerabilities, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
A limited set so far — we surface every cited disclosure we’ve extracted for ENOV. More may follow as additional filings are processed.
In its own words
What could break it.
Commodity & input dependence
- Implant-metals and polymer input dependence — cobalt-chromium, stainless-steel and titanium alloys, UHMWPE (Recon implants) and EVA foam (bracing)medium
Enovis's medical-device cost base depends on specialty metals and polymers: cobalt-chromium alloys, stainless-steel alloys, titanium alloys and ultra-high-molecular-weight polyethylene (UHMWPE) used in its Reconstructive surgical implants, and foam ethylene-vinyl-acetate copolymer used in its Prevention & Recovery bracing/vascular products. While it generally uses more than one supplier to mitigate shortage risk, a significant change in the supply or price of these implant metals/polymers — or disruption of suppliers in China/Asia — could materially affect results. Titanium and cobalt-chrome are also exposed to defense/aerospace-driven demand and geopolitical supply concentration. A core orthopedic-materials commodity dependence.
“Our principal raw materials include foam ethylene-vinyl-acetate copolymer used in our bracing and vascular products within P&R, and cobalt-chromium alloys, stainless-steel alloys, titanium alloys, and ultra-high-molecular-weight polyethylene used in our Recon surgical implant products.”
SEC filing →As of 2026
Regulatory & policy
- Import tariffs on raw materials/components — U.S. tariffs on goods from Canada, China and Mexico raise input costs and impair sourcing flexibility; net tariffs already pressured EBITDAmedium
Enovis sources raw materials, component parts and supplies from global sources, and flags that tariffs may increase costs and impair sourcing flexibility for those inputs, with further trade restrictions, retaliatory measures or additional tariffs raising input costs. It notes the U.S. has imposed/threatened tariffs on goods from Canada, China, Mexico and many other countries (with retaliation), and that the net impact of new tariffs already pressured its Adjusted EBITDA margin. With ~42% of sales (and significant supply) outside the U.S. — concentrated in Europe (post-Lima) and Asia-Pacific — tariff escalation directly compresses margins and sourcing options. A specific, realized tariff/trade-policy exposure.
“Tariffs may increase the cost of, and impair sourcing flexibility for raw materials, component parts and supplies, and further trade restrictions, retaliatory trade measures, or additional tariffs could result in higher input costs for our products.”
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch